MYCN and non-small cell lung carcinoma: To that end, the experimental evidence indicates that arsenic compounds such as As2O3, arsenic sulfide, and tetra arsenic hexoxide act as promising drug repurposing candidates against NSCLC because of their ability to target oncogenes, including growth factors GAS-1, N-MYC, and Gli1.